- Home
- BME vs ESPR Comparison
BME vs ESPR Comparison
Compare BME & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- ESPR
- Stock Information
- Founded
- BME 2005
- ESPR 2008
- Country
- BME United States
- ESPR United States
- Employees
- BME N/A
- ESPR N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- ESPR Health Care
- Exchange
- BME Nasdaq
- ESPR Nasdaq
- Market Cap
- BME 487.9M
- ESPR 534.3M
- IPO Year
- BME N/A
- ESPR 2013
- Fundamental
- Price
- BME $37.96
- ESPR $2.52
- Analyst Decision
- BME
- ESPR Buy
- Analyst Count
- BME 0
- ESPR 6
- Target Price
- BME N/A
- ESPR $6.50
- AVG Volume (30 Days)
- BME 34.0K
- ESPR 7.0M
- Earning Date
- BME 01-01-0001
- ESPR 11-06-2025
- Dividend Yield
- BME 6.26%
- ESPR N/A
- EPS Growth
- BME N/A
- ESPR N/A
- EPS
- BME 1.44
- ESPR N/A
- Revenue
- BME N/A
- ESPR $268,125,000.00
- Revenue This Year
- BME N/A
- ESPR $13.05
- Revenue Next Year
- BME N/A
- ESPR N/A
- P/E Ratio
- BME $28.37
- ESPR N/A
- Revenue Growth
- BME N/A
- ESPR N/A
- 52 Week Low
- BME $35.53
- ESPR $0.69
- 52 Week High
- BME $43.20
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- BME 62.54
- ESPR 47.71
- Support Level
- BME $35.95
- ESPR $2.35
- Resistance Level
- BME $38.01
- ESPR $3.41
- Average True Range (ATR)
- BME 0.42
- ESPR 0.18
- MACD
- BME 0.12
- ESPR -0.03
- Stochastic Oscillator
- BME 81.31
- ESPR 9.79
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.